"Selective inhibition of interleukin (IL)-23 with the investigational drug risankizumab may be more effective in treating psoriasis than ustekinumab, a less specific drug, a phase 2 study suggests.
Results were published online April "...
The highest dose tested in humans (0.75 mg/kg intravenous) was associated with chills, headache, arthralgia, and sinusitis within one day of dosing. Patients who have been inadvertently administered an excess of the recommended dose should be closely monitored for effects on total lymphocyte count and CD4+ T lymphocyte count.
AMEVIVE® should not be administered to patients infected with HIV. AMEVIVE® reduces CD4+ T lymphocyte counts, which might accelerate disease progression or increase complications of disease in these patients [see WARNINGS AND PRECAUTIONS].This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/29/2016
Additional Amevive Information
Amevive - User Reviews
Amevive User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.